Quantification of the External Validity of Randomized Controlled Trials Supporting Clinical Care Guidelines: The Case of Thromboprophylaxis

被引:0
作者
Abdallah, Sami Morin-Ben [1 ]
Dutilleul, Aurore [1 ]
Nadon, Valerie [1 ]
Yang, Ji Wei [1 ]
Marchand-Senecal, Xavier [1 ]
Nguyen, Paul Van [1 ]
Lamarre-Cliche, Maxime [1 ]
Wistaff, Robert [1 ]
Kolan, Christophe [1 ]
Laskine, Mikhael [1 ]
Durand, Madeleine [1 ]
机构
[1] Univ Montreal, Ctr Rech, Ctr Hosp, 3840 St Urbain St, Montreal, PQ H2V 3B3, Canada
关键词
American College of Chest Physicians guidelines; Exclusion criteria; External validity; Medical hospitalized patients; Padua score; Pharmacological thromboprophylaxis; Risk scores; MOLECULAR-WEIGHT HEPARIN; HOSPITALIZED MEDICAL PATIENTS; DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; PREVENTION; PLACEBO; PROPHYLAXIS; INPATIENTS; MORTALITY; RISK;
D O I
10.1016/j.amjmed.2016.02.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Clinical guidelines are based on the results of several randomized controlled trials. However, due to the stringent exclusion criteria of these trials, their external validity may be low. We aimed to evaluate the external validity of the randomized controlled trials cited in the American College of Chest Physicians guidelines for the use of pharmacological thromboprophylaxis in hospitalized medical patients. METHODS: We conducted a cross-sectional, chart-review study of a random sample of patients admitted between July 1, 2013 and June 30, 2014 to the Internal Medicine ward of a large Canadian teaching university hospital. We identified the proportion of our population presenting exclusion criteria used in the randomized controlled trials cited in support of clinical care guidelines on thromboprophylaxis in the medical setting. RESULTS: Nine trials were identified for a total of 28,793 included patients following 23 distinct exclusion criteria. We included 429 patients. Median age was 65 years (interquartile ratio 51-77 years), and 236 (55%) were males. Of those not already anticoagulated at admission (n = 351), between 26% and 67% (weighted average, 51%) of our population presented at least one exclusion criterion, making them ineligible to be enrolled in randomized controlled trials. When restricting our population to patients with an indication for thromboprophylaxis based on a Padua risk score at admission >= 4, 21% to 76% (weighted average 55%) were ineligible to be enrolled in individual trials. CONCLUSIONS: Our cross-sectional study illustrates that the external validity of randomized controlled trials cited in the guidelines was low in our population, and lower when applying the risk-stratification tool recommended by guidelines. This can bias the clinicians toward treating patients that were not represented in the supporting evidence. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:740 / 745
页数:6
相关论文
共 50 条
  • [41] Effect sizes in ongoing randomized controlled critical care trials
    Ridgeon, Elliott E.
    Bellomo, Rinaldo
    Aberegg, Scott K.
    Mac Sweeney, Rob
    Varughese, Rachel S.
    Landoni, Giovanni
    Young, Paul J.
    CRITICAL CARE, 2017, 21
  • [42] Perspective: Peer Evaluation of Recommendations for CONSORT Guidelines for Randomized Controlled Trials in Nutrition
    Weaver, Connie
    Ahles, Sanne
    Murphy, Karen J.
    Shyam, Sangeetha
    Cade, Janet
    Plat, Jogchum
    Schwingshackl, Lukas
    Roche, Helen M.
    Lachat, Carl
    Minihane, Anne-Marie
    Rigutto-Farebrother, Jessica
    ADVANCES IN NUTRITION, 2024, 15 (01)
  • [43] Guidelines of the International Headache Society for Controlled Clinical Trials in Cluster Headache
    Schoenen, Jean
    Snoer, Agneta Henriette
    Brandt, Roemer B.
    Fronczek, Rolf
    Wei, Diana Y.
    Chung, Chin-Sang
    Diener, Hans-Christoph
    Dodick, David W.
    Fontaine, Denys
    Goadsby, Peter J.
    Matharu, Manjit Singh
    May, Arne
    McGinley, James S.
    Tepper, Stewart J.
    Jensen, Rigmor Hojland
    Ferrari, Michel D.
    CEPHALALGIA, 2022, 42 (14) : 1450 - 1466
  • [44] The reproducibility of interventional radiology randomized controlled trials and external validation of a classification system
    Aslan, Assala
    Stevens, Christopher
    Aldine, Amro Saad
    Mamilly, Aldine Ahmed
    De Alba, Luis
    Arevalo, Octavio
    Ahuja, Chaitanya
    Cuellar, Hugo H.
    DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, 2023, 29 (03): : 529 - 534
  • [45] Clinical decision support systems to optimize adherence to anticoagulant guidelines in patients with atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials
    Amin, Ahmed Mazen
    Ghaly, Ramy
    Abuelazm, Mohamed T.
    Ibrahim, Ahmed A.
    Tanashat, Mohammad
    Arnaout, Moumen
    Altobaishat, Obieda
    Elshahat, Ahmed
    Abdelazeem, Basel
    Balla, Sudarshan
    THROMBOSIS JOURNAL, 2024, 22 (01):
  • [46] Atrial fibrillation screening and clinical outcomes: a meta-analysis of randomized controlled trials
    Nyaga, Ulrich Flore
    Kamtchum-Tatuene, Joseph
    Nouthe, Brice
    Nkoke, Clovis
    Noubiap, Jean Jacques
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2025, : 282 - 290
  • [47] Declining clinical benefit of ICD in heart failure patients: Temporal trend of mortality outcomes from randomized controlled trials
    Disertori, Marcello
    Mase, Michela
    Rigoni, Marta
    Nollo, Giandomenico
    Ravelli, Flavia
    JOURNAL OF CARDIOLOGY, 2020, 75 (02) : 148 - 154
  • [48] Automated causal inference in application to randomized controlled clinical trials
    Wu, Ji Q.
    Horeweg, Nanda
    de Bruyn, Marco
    Nout, Remi A.
    Jurgenliemk-Schulz, Ina M.
    Lutgens, Ludy C. H. W.
    Jobsen, Jan J.
    Van der Steen-Banasik, Elzbieta M.
    Nijman, Hans W.
    Smit, Vincent T. H. B. M.
    Bosse, Tjalling
    Creutzberg, Carien L.
    Koelzer, Viktor H.
    NATURE MACHINE INTELLIGENCE, 2022, 4 (05) : 436 - +
  • [49] Clinical outcomes of atrial fibrillation screening: a meta-analysis of randomized controlled trials
    Langen, Ville
    Winsten, Aleksi K.
    Airaksinen, K. E. Juhani
    Teppo, Konsta
    ANNALS OF MEDICINE, 2025, 57 (01)
  • [50] Clinical drug trials in general practice: how well are external validity issues reported?
    Anja Maria Brænd
    Jørund Straand
    Atle Klovning
    BMC Family Practice, 18